Figure 2From: Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study)Mean% change from baseline in LDL-C after 6 weeks of treatment.Back to article page